Description: Femasys is a biomedical company focused on transforming women’s healthcare worldwide by developing novel solutions and next-generation advancements providing significant clinical impact to address severely underserved areas. With an initial focus in the area of reproductive health, its two lead product candidates offer solutions to improve patient care and health economics: FemBloc, a first and only non-surgical product for permanent birth control and FemaSeed, a first and only directed sperm delivery product for infertility treatment. Femasys’ FemVue product for fallopian tube assessment by ultrasound is currently marketed in the United States as its main commercial priority. Femasys has also developed a novel technology platform for tissue sampling intended to be marketed alongside our other women-specific medical products in the physician’s office setting.
Home Page: www.femasys.com
FEMY Technical Analysis
3950 Johns Creek Court
Suwanee,
GA
30024
United States
Phone:
770 500 3910
Officers
| Name | Title |
|---|---|
| Ms. Kathy Lee-Sepsick | Founder & CEO and Pres |
| Mr. Daniel Scott Currie | SVP of Operations & Sec. |
| Mr. Dov Elefant | Chief Financial Officer |
| Ms. Mary An Merchant J.D., Ph.D. | VP of Counsel & Intellectual Property |
| Mr. Steven P. Damon | VP of Bus. Devel. |
| Mr. Todd A. Creech MBA | Chief Financial Advisor |
| Dr. Jeffrey Marcus M.D., M.S. | Chief Medical Advisor |
| Dr. Edward G. Evantash M.D. | Chief Medical Officer |
| Ms. Christine Thomas | Sr. VP of Regulatory & Clinical Affairs |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 3.9333 |
| Price-to-Book MRQ: | 0.7085 |
| Price-to-Sales TTM: | 9.9399 |
| IPO Date: | 2021-06-18 |
| Fiscal Year End: | December |
| Full Time Employees: | 27 |